Microscopy Leader

Microscopy Leader

22.08.2014 - Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.

Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.


Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

13.05.2014 Isarna Therapeutics GmbH (Munich) has named Elizabeth Czerepak to lead the company’s new office location in New York City as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics

Czerepak has a track record of 21 years in the biopharma industry and nine years as a venture capital investor at JP Morgan and Bear Stearns. She has served in various executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. Prior to CGI, Czerepak worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

06.05.2014 The European Food Safety Authority’s Management Board has nominated Dr. Bernhard Url as EFSA’s next Executive Director.


Following the departure of former Director Catherine Geslain-Lanéelle, Url has been EFSA’s acting Executive Director since the autumn of 2013. A qualified veterinarian by training, he brings high-level management experience from public and private food-safety organisations to the role, most recently as Managing Director for the Austrian Agency for Health and Food Safety (AGES). Until March 2012, Url served as a member of EFSA’s Management Board.

29.04.2014 Canbex Therapeutics Ltd has hired Alberto Lledó as its new Chief Medical Officer.

Canbex SL

Lledó will lead Canbex’s preparations in proof-of-concept trials for VSN16R, a small molecule for the treatment of spasticity in multiple sclerosis. Lledó is a Senior Consultant Neurologist at the Clínica Creu Blanca (Barcelona), and spent sixteen years at Eli Lilly. He will take over as Chief Medical Officer from Dr. Miroslav Ravic, who is guiding the company through the completion of its Phase I study. 

24.04.2014 Roche’s pRED unit has a new head of oncology and translational research.

Vanderbilt University Medical Center/Susan Urmy

William Pao, currently director at the Hematology-Oncology division and Personalised Cancer Medicine unit at Vanderbilt University Medical Center, will lead Roche’s discovery, translational medicine and early development of innovative oncology medicines. Pao, who has focused on academic clinical research in the past, is one of the world’s top oncology experts.

17.04.2014 Irish antibody developer Prothena Corporation plc has named Tara Nickerson as its Chief Business Officer.

Prothena Corp.

Previously she held the position of Head of Corporate and Business Development at the company, where she was instrumental during Prothena’s demerger from Elan and Prothena’s worldwide collaboration with Roche to develop and commercialise antibodies that target alpha-synuclein. Prior to Elan, Nickerson was a senior scientist at Celera Genomics (Axys Pharmaceuticals). 

15.04.2014 Geneva-based antibody developer Novimmune SA has appointed Andrew Oakley as its new CFO.


The finance expert has been the CFO and Vice President of Actelion Pharmaceuticals U.S., Inc. since January of 2003. Prior to that, he held executive positions in major multinational building material companies, and spent several years as an equity analyst with banks in Australia, the UK and the US. Oakley has been a member of the Australian Institute of Chartered Accountants since 1987.

08.04.2014 Germany’s Merck KGaA (Darmstadt) has hired the former head of Boehringer Ingelheim’s biopharmaceuticals development team to lead its biosimilar unit, which was set up in 2012.


Prior to the stint at Boehringer, Simon Sturge was CEO of Dutch biotech OctoPlus NV, and he also acted as CEO of Vernalis plc (UK). In the past, Sturge has held several roles of increasing seniority – from Business Development, Marketing and Operations to CEO at Lonza Biologics, as well as at Celltech Biologics and at AstraZeneca. The native of Britain was awarded the UK Mediscience CEO of the Year award in 2005. Sturge succeeds Thierry Hulot, who created Merck’s biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of 2013. Along with Sturge, Merck has also strengthened its team internally with Friederike Rotsch, who has now taken over as chief legal advisor. 

27.03.2014 Ghent-based AgroSavfe BV has added to its management team Maria Abad-Molina new Head of Product & Business Development and Dr. Miguel De Bolle (Photo) as Head of Research.


While Bolle will head R&D to advance the company's Agrobody-technology platform for the development of innovative formulations for the sustainable use of crop protection products, Abad-Molina will be responsible for product development and registration at the company. A trained agronomical engineer who holds an Executive MBA, Abad--Molina has more than 20 years of experience in the crop protection and plant biotech-nology industries. Before joining the AgroSavfe management team, she was on the management team of BASF Plant Science subsidiary CropDesign, where she led global activities for placing plant protection products in the market, including the firm's top herbicide in terms of sales.

25.03.2014 British late-stage drug co-developer Avillion LLP appointed Dr. Allison Jeynes-Ellis to the post of Chief Executive Officer in February.

Dianna Bonner

The company’s cofounder and former CMO previously worked in senior roles at various pharmaceutical companies, including Wyeth, Bristol-Myers Squibb and Novartis. She has also acted as an independent consultant to many companies – including CAT and Genentech – as well as government bodies and medical research charities.

Vorherige Seite3/20Nächste Seite


All Events

Stock list

All quotes


  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%


  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%


  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%


  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%


  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%


  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014

Current issue

All issues

Product of the week